Literature DB >> 25410207

Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Amanda J Griffin1, Deborah D Crane1, Tara D Wehrly1, Catharine M Bosio2.   

Abstract

Francisella tularensis is an intracellular, Gram-negative bacterium that causes the fatal disease tularemia. Currently, there are no licensed vaccines for tularemia and the requirements for protection against infection are poorly defined. To identify correlates of vaccine-induced immunity against tularemia, we compared different strains of the live vaccine strain (LVS) for their relative levels of virulence and ability to protect C57BL/6 mice against challenge with virulent F. tularensis strain SchuS4. Successful vaccination, as defined by survival of C57BL/6 mice, was correlated with significantly greater numbers of effector T cells in the spleen and lung. Further, lung cells and splenocytes from fully protected animals were more effective than lung cells and splenocytes from vaccinated but nonimmune animals in limiting intracellular replication of SchuS4 in vitro. Together, our data provide a unique model to compare efficacious vaccines to nonefficacious vaccines, which will enable comprehensive identification of host and bacterial components required for immunization against tularemia.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410207      PMCID: PMC4278928          DOI: 10.1128/CVI.00648-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  41 in total

1.  Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine.

Authors:  H T EIGELSBACH; J J TULIS; E L OVERHOLT; W R GRIFFITH
Journal:  Proc Soc Exp Biol Med       Date:  1961-12

2.  Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection.

Authors:  Yun Hee Jeong; Bo-Young Jeon; Sun-Hwa Gu; Sang-Nae Cho; Sung Jae Shin; Jun Chang; Sang-Jun Ha
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

3.  Low dose aerosol infection of mice with virulent type A Francisella tularensis induces severe thymus atrophy and CD4+CD8+ thymocyte depletion.

Authors:  Wangxue Chen; Rhonda Kuolee; John W Austin; Hua Shen; Yanming Che; J Wayne Conlan
Journal:  Microb Pathog       Date:  2005-10-28       Impact factor: 3.738

4.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Authors:  Rebecca V Anderson; Deborah D Crane; Catharine M Bosio
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

5.  Minimal requirements for murine resistance to infection with Francisella tularensis LVS.

Authors:  K L Elkins; T R Rhinehart-Jones; S J Culkin; D Yee; R K Winegar
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.

Authors:  Susan Twine; Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  Vaccine       Date:  2012-04-03       Impact factor: 3.641

7.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

8.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

9.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

10.  Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia.

Authors:  Deborah D Crane; Dana P Scott; Catharine M Bosio
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more
  24 in total

1.  Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.

Authors:  Linxiao Chen; Jenny L Valentine; Chung-Jr Huang; Christine E Endicott; Tyler D Moeller; Jed A Rasmussen; Joshua R Fletcher; Joseph M Boll; Joseph A Rosenthal; Justyna Dobruchowska; Zhirui Wang; Christian Heiss; Parastoo Azadi; David Putnam; M Stephen Trent; Bradley D Jones; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

2.  Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Tara D Wehrly; Ian Leighton; Patrick Hanley; Jamie Lovaglio; Brian J Smith; Catharine M Bosio
Journal:  J Immunol       Date:  2022-02-11       Impact factor: 5.422

3.  Contribution of Lipid Mediators in Divergent Outcomes following Acute Bacterial and Viral Lung Infections in the Obese Host.

Authors:  Benjamin Schwarz; Lydia M Roberts; Eric Bohrnsen; Forrest Jessop; Tara D Wehrly; Carl Shaia; Catharine M Bosio
Journal:  J Immunol       Date:  2022-08-24       Impact factor: 5.426

4.  Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies.

Authors:  Taylor C Stevenson; Colette Cywes-Bentley; Tyler D Moeller; Kevin B Weyant; David Putnam; Yung-Fu Chang; Bradley D Jones; Gerald B Pier; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-19       Impact factor: 11.205

5.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

6.  Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Deborah D Crane; Tara D Wehrly; Joshua R Fletcher; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

7.  Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.

Authors:  Elizabeth Stinson; Le'Kneitah P Smith; Kelly Stefano Cole; Eileen M Barry; Douglas S Reed
Journal:  Pathog Dis       Date:  2016-08-09       Impact factor: 3.166

Review 8.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

9.  Border Patrol Gone Awry: Lung NKT Cell Activation by Francisella tularensis Exacerbates Tularemia-Like Disease.

Authors:  Timothy M Hill; Pavlo Gilchuk; Basak B Cicek; Maria A Osina; Kelli L Boyd; Douglas M Durrant; Dennis W Metzger; Kamal M Khanna; Sebastian Joyce
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

10.  Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.

Authors:  Sukalyani Banik; Ahd Ahmed Mansour; Ragavan Varadharajan Suresh; Sherri Wykoff-Clary; Meenakshi Malik; Alison A McCormick; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.